Biologic drugs must be managed to contain costs

The Insurance and Investment Journal – Susan Yellin

 An aging population plus the growth of new “biologic” drugs are increasing the cost of drug plans for many participants. But a recent conference held in Toronto was told that plan sponsors willing to provide meaningful information and communicate changes effectively with participants should see sustainability for those plans over the long term.

Read More…